维生素D治疗前列腺癌的Meta分析

Vitamin D in the Treatment of Prostate Cancer:A Meta-Analysis

目的：评价补充维生素D对前列腺癌患者病死率及不良反应发生率的影响。方法：用计算机检索PubMed、The Cochrane Library、CNKI、万方数据库和维普数据库,检索时限均为从建库至2014年4月,同时手动检索（手检）相关杂志,查找比较维生素D和安慰剂治疗前列腺癌的随机对照试验（RCT）。由2名研究者按纳入与排除标准独立筛选文献,提取资料和评价质量后采用RevMan5.2软件进行统计分析。结果：共纳入3篇随机对照试验,共计2243例患者。Meta分析结果显示,维生素D能降低前列腺癌病死率[OR=0.23,95%CI：0.18~0.29],不良事件未见报道。结论：维生素D能降低前列腺癌的病死率。但该分析为二次研究,纳入的原始文献质量不一,而且评价过程也可能存在偏倚,故上述结论尚需进一步开展大规模的基础和临床研究来验证。

Objective：To evaluate the effects of vitamin D supplement on the mortality and incidence rate of adverse events of prostate cancer. Methods：Date from PubMed, The Cochrane Library, CNKI, Wanfang Data and VIP database during the date of database establishment and April 2014 were searched online, while relevant journals were searched manually, for all rando- mized controlled trials （RCTs） of comparison between vitamin D and placebo in the treatment of prostate cancer. The data ex- traction and quality assessment were conducted according to inclusion and exclusion criteria by two reviewers independently with RevMan5.2. Results： A total of 3 RCTs involving 2243 cases met the inclusion criteria. Vitamin D could reduce the mor tality of prostate cancer[OR = 0.23,95%CI： IL- 18-0.29], as meta-analysis demonstrated. There was no report on adverse e- vents. Conclusions： Vitamin D could reduce the mortality of prostate cancer. However, the analysis is secondary study, of which the included literatures differ in quality, and there may be bias in analytical process. Thus, basic and clinical researches with large-scale and high quality should be performed to confirm the above conclusion.